{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:49:33Z","timestamp":1776412173814,"version":"3.51.2"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS086312"],"award-info":[{"award-number":["R01NS086312"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS110519"],"award-info":[{"award-number":["R01NS110519"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24AI184270"],"award-info":[{"award-number":["K24AI184270"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cryptococcal meningitis is a life-threatening infection of the central nervous system. Early fungicidal activity (EFA), which measures how quickly Cryptococcus yeasts are cleared from cerebrospinal fluid (CSF) over time, is a key endpoint in phase 2 antifungal clinical trials. EFA is commonly estimated via a 2-step approach, where simple linear regressions are first fit to each individual's longitudinal measurements, and the slopes are then aggregated for statistical inference. Alternatively, a linear mixed model can estimate individual and group-level effects in one model. A systematic comparison of these methods is needed to understand and clarify their differences in analyzing EFA data in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic literature review to summarize the usage and reporting of both methods in cryptococcal meningitis clinical trials. We then evaluated their performance and operating characteristics under various simulation scenarios and applied both approaches to data from a phase 2 trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 2-step approach and mixed model approach yielded discrepant CSF EFA estimates across literature review, simulation experiments, and real data analysis. The 2-step approach using linear regression produced steeper estimates and larger estimated treatment effects. The linear mixed model yielded smaller standard errors but estimates were biased toward the null, especially when early culture sterility was common.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The 2-step approach is preferred for estimating EFA in cryptococcal meningitis studies, especially when early culture sterility occurs. EFA estimates should not be interpreted or compared across studies without accounting for the underlying statistical models and data preprocessing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag159","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:52:38Z","timestamp":1773838358000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessing Statistical Methods for Estimating the Cerebrospinal Fluid Early Fungicidal Activity as an Endpoint for Cryptococcal Meningitis Clinical Trials: A Systematic Review and Simulation Study"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6724-0676","authenticated-orcid":false,"given":"Monica","family":"Fuszard","sequence":"first","affiliation":[{"name":"Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4715-0060","authenticated-orcid":false,"given":"David R","family":"Boulware","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4747-3687","authenticated-orcid":false,"given":"Biyue","family":"Dai","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"key":"2026041703022091500_ofag159-B1","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","article-title":"The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis","volume":"22","author":"Rajasingham","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026041703022091500_ofag159-B2","doi-asserted-by":"crossref","first-page":"e0004429","DOI":"10.1371\/journal.pntd.0004429","article-title":"Funding and innovation in diseases of neglected populations: the paradox of cryptococcal meningitis","volume":"10","author":"Rodrigues","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2026041703022091500_ofag159-B3","author":"World Health Organization"},{"key":"2026041703022091500_ofag159-B4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/jof5030065","article-title":"Diagnosis and management of central nervous system cryptococcal infections in HIV-infected adults","volume":"5","author":"Skipper","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"2026041703022091500_ofag159-B5","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","article-title":"Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial","volume":"363","author":"Brouwer","year":"2004","journal-title":"Lancet"},{"key":"2026041703022091500_ofag159-B6","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/cid\/ciaa016","article-title":"Cerebrospinal fluid early fungicidal activity as a surrogate endpoint for cryptococcal meningitis survival in clinical trials","volume":"71","author":"Pullen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B7","doi-asserted-by":"crossref","first-page":"e0159727","DOI":"10.1371\/journal.pone.0159727","article-title":"Early fungicidal activity as a candidate surrogate endpoint for all-cause mortality in cryptococcal meningitis: a systematic review of the evidence","volume":"11","author":"Montezuma-Rusca","year":"2016","journal-title":"PLoS One"},{"key":"2026041703022091500_ofag159-B8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/mmy\/myv104","article-title":"Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis","volume":"54","author":"Dyal","year":"2016","journal-title":"Med Mycol"},{"key":"2026041703022091500_ofag159-B9","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal combinations for treatment of cryptococcal meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"N Engl J Med"},{"key":"2026041703022091500_ofag159-B10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-dose liposomal amphotericin B treatment for cryptococcal meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N Engl J Med"},{"key":"2026041703022091500_ofag159-B11","doi-asserted-by":"crossref","first-page":"e68929","DOI":"10.7554\/eLife.68929","article-title":"An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis","volume":"10","author":"Ngan","year":"2021","journal-title":"Elife"},{"key":"2026041703022091500_ofag159-B12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1473-3099(19)30127-6","article-title":"Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial","volume":"19","author":"Rhein","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026041703022091500_ofag159-B13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial","volume":"77","author":"Boulware","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jrsm.1303","article-title":"A comparison of one-stage vs two-stage individual patient data meta-analysis methods: a simulation study","volume":"9","author":"Kontopantelis","year":"2018","journal-title":"Res Synth Methods"},{"key":"2026041703022091500_ofag159-B15","volume-title":"Cluster randomised trials","author":"Hayes","year":"2017"},{"key":"2026041703022091500_ofag159-B16","volume-title":"Applied longitudinal analysis","author":"Fitzmaurice","year":"2012"},{"key":"2026041703022091500_ofag159-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"key":"2026041703022091500_ofag159-B18","unstructured":"Lenth \u00a0RV.\n           \u00a0emmeans: Estimated marginal means, aka least-squares means. \u00a0Comprehensive R Archive Network (CRAN), 2024."},{"key":"2026041703022091500_ofag159-B19","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-21706-2","volume-title":"MASS: modern applied statistics with S","author":"Venables","year":"2002"},{"key":"2026041703022091500_ofag159-B20","unstructured":"van den Boogaart \u00a0KG, Tolosana-Delgado \u00a0R, Bren \u00a0M. \u00a0compositions: Compositional data analysis: R package version 2.0-9. 2025."},{"key":"2026041703022091500_ofag159-B21","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1128\/AAC.01188-06","article-title":"Oral versus intravenous flucytosine in patients with human immunodeficiency virus\u2013associated cryptococcal meningitis","volume":"51","author":"Brouwer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026041703022091500_ofag159-B22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1086\/518607","article-title":"Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole","volume":"45","author":"Bicanic","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/588792","article-title":"High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial","volume":"47","author":"Bicanic","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B24","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1086\/593194","article-title":"Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda","volume":"47","author":"Longley","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/QAI.0b013e3181a56f2e","article-title":"Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study","volume":"51","author":"Bicanic","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026041703022091500_ofag159-B26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/604716","article-title":"Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients","volume":"49","author":"Bicanic","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1086\/649861","article-title":"Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi","volume":"50","author":"Nussbaum","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/cid\/cir745","article-title":"Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis","volume":"54","author":"Loyse","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jinf.2011.10.014","article-title":"Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis","volume":"64","author":"Muzoora","year":"2012","journal-title":"J Infect"},{"key":"2026041703022091500_ofag159-B30","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/QAD.0b013e328354b419","article-title":"A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis","volume":"26","author":"Jackson","year":"2012","journal-title":"AIDS"},{"key":"2026041703022091500_ofag159-B31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","article-title":"Adjunctive interferon-\u03b3 immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial","volume":"26","author":"Jarvis","year":"2012","journal-title":"AIDS"},{"key":"2026041703022091500_ofag159-B32","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cid\/cit019","article-title":"Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis","volume":"56","author":"Bisson","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B33","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N Engl J Med"},{"key":"2026041703022091500_ofag159-B34","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/infdis\/jit099","article-title":"The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis","volume":"207","author":"Jarvis","year":"2013","journal-title":"J Infect Dis"},{"key":"2026041703022091500_ofag159-B35","doi-asserted-by":"crossref","first-page":"e1004754","DOI":"10.1371\/journal.ppat.1004754","article-title":"Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis","volume":"11","author":"Jarvis","year":"2015","journal-title":"PLoS Pathog"},{"key":"2026041703022091500_ofag159-B36","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMoa1509024","article-title":"Adjunctive dexamethasone in HIV-associated cryptococcal meningitis","volume":"374","author":"Beardsley","year":"2016","journal-title":"N Engl J Med"},{"key":"2026041703022091500_ofag159-B37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study","volume":"16","author":"Rhein","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026041703022091500_ofag159-B38","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/cid\/ciy725","article-title":"Do intracerebral cytokine responses explain the harmful effects of dexamethasone in human immunodeficiency virus\u2013associated cryptococcal meningitis?","volume":"68","author":"Beardsley","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s15010-017-1059-3","article-title":"Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: a single Mexican center experience","volume":"46","author":"Villanueva-Lozano","year":"2018","journal-title":"Infection"},{"key":"2026041703022091500_ofag159-B40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/ciy515","article-title":"Short-course high-dose liposomal amphotericin B for human immunodeficiency virus\u2013associated cryptococcal meningitis: a phase 2 randomized controlled trial","volume":"68","author":"Jarvis","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B41","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/myc.12995","article-title":"Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania","volume":"62","author":"Katende","year":"2019","journal-title":"Mycoses"},{"key":"2026041703022091500_ofag159-B42","doi-asserted-by":"crossref","first-page":"e0159224","DOI":"10.1128\/mbio.01592-24","article-title":"Integration of genomic and pharmacokinetic data to predict clinical outcomes in HIV-associated cryptococcal meningitis","volume":"15","author":"Stott","year":"2024","journal-title":"mBio"},{"key":"2026041703022091500_ofag159-B43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/cid\/ciae413","article-title":"Implementation of single high-dose liposomal amphotericin B based induction therapy for treatment of HIV-associated cryptococcal meningitis in Uganda: a comparative prospective cohort study","volume":"80","author":"Gakuru","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/cid\/ciae326","article-title":"Comparison of early fungicidal activity and mortality between daily liposomal amphotericin B and daily amphotericin B deoxycholate for cryptococcal meningitis","volume":"80","author":"Kimuda","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026041703022091500_ofag159-B45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group","volume":"337","author":"van der Horst","year":"1997","journal-title":"N Engl J Med"},{"key":"2026041703022091500_ofag159-B46","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","article-title":"Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis","volume":"370","author":"Boulware","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag159\/67461869\/ofag159.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/4\/ofag159\/68099363\/ofag159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/4\/ofag159\/68099363\/ofag159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:02:44Z","timestamp":1776409364000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag159\/8534480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag159","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,22]]},"article-number":"ofag159"}}